5 questions answered from cited research · Plain language
Leptomeningeal metastasis from pancreatic cancer is rare and usually has a very short median survival of 1 to 2 months, but rare individual cases have lived longer with intensive treatment [1].
Read the full answer →Intrathecal therapy can shrink tumors and ease neurological symptoms in some patients with leptomeningeal metastasis, but benefits vary widely and it is not a cure.
Read the full answer →For EGFR-mutant lung cancer that has spread to the lining of the brain (leptomeningeal metastasis), studies point to osimertinib, sometimes combined with bevacizumab, and pemetrexed as treatments linked to longer survival.
Read the full answer →Intrathecal chemotherapy through an Ommaya reservoir is a standard way to treat leptomeningeal metastasis, and comparative evidence suggests it may improve disease control and survival versus repeated lumbar puncture [3][7].
Read the full answer →Intrathecal chemotherapy can shrink or stabilize leptomeningeal metastasis and may extend survival in some patients, but benefit varies by cancer type and the evidence is not uniform.
Read the full answer →